Background Recently, a variety of clinical trials have shown that apatinib, a small-molecule
anti-angiogenic drug, exerts promising inhibitory effects on multiple solid tumors, including …

Apatinib is a multitarget tyrosine kinase inhibitor marketed in China for the treatment of
advanced gastric cancer (GC) and hepatocellular carcinoma (HCC). It has also been used …

The mortality of lung cancer is surprising, even though the development of different
treatments and diagnosis methods. Besides, non-small cell lung cancer (NSCLC) takes a …

Background Ramucirumab plus erlotinib (RAM+ ERL) demonstrated superior progression-
free survival (PFS) in RELAY, a randomised Phase 3 trial in patients with untreated …

Background Although targeted agents have been gradually applied in the treatment of
HER2-mutated non-small cell lung cancer (NSCLC) in recent years, patients' therapeutic …

Purpose: Although gefitinib prolonged the progression-free survival (PFS) of patients with
non–small cell lung cancer (NSCLC), unpredictable resistance limited its clinical efficacy …

Although anti-angiogenic agents have been of limited use in the treatment of non-small cell
lung cancer (NSCLC) until recently, further roles for the use of angiogenesis inhibition have …

Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …

Importance Use of tyrosine kinase inhibitors (TKIs) is the standard therapy for epidermal
growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC) with brain …

Background This study evaluated whether an addition of bevacizumab to erlotinib improves
clinical outcomes in patients with advanced EGFR‐mutated non–small cell lung cancer …